View Clinical Trial (Medical Research Study)
Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation - NCT00364650-98122(Clinical Trial 147709)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Seattle |
|
State:
|
|
WA |
| Zip Code: |
|
98122 |
| Conditions: |
|
Renal Transplantation |
| Purpose: |
|
We hypothesize that the administration of a combination of high numbers of probiotic
bacteria will maintain normal bowel function and significantly moderate or obviate
Immunosuppression Associated Diarrhea following kidney transplantation.
|
| Study summary: |
|
Immunosuppression following organ transplantation is associated with a myriad of
gastrointestinal complications including severe diarrhea. Mycophenolate mofetil (MMF) is the
immunosuppressant most often associated with this plaguing symptom. A retrospective study of
patients from 10 US transplant centers receiving MMF immunosuppression after kidney
transplantation showed that nearly 50% of patients suffered from at least one
gastrointestinal symptom within the first 6 months after transplantation. (Tierce 2005) The
majority of these patients have diarrhea. However, Immunosuppression Associated Diarrhea
(IAD) is often observed in association with other immunosuppressive agents as well. It is
the investigator's observation that IAD is equally problematic whether the immunosuppressive
regimen includes MMF or not. When IAD is severe it can be difficult for the recipient to
maintain adequate levels of immunosuppression. Not infrequently, IAD is so distressing that
a recipient's immunosuppressive medications are tapered, changed or stopped. During these
times of drug manipulation, patients are at risk for early acute rejection. Approximately
30% of renal transplant patients who have their MMF regimen adjusted or discontinued suffer
an episode of acute rejection. Reversing a rejection episode is expensive and adds
significant risks for the recipient and long-term allograft survival. Thus, a strategy to
support and maintain normal healthy bowel function moderating or obviating IAD is highly
desirable.
Repopulation of the normal intestinal microflora in kidney transplant patients after kidney
transplantation may maintain normal bowel function. This study is designed to test the
hypothesis that the administration of a food supplement probiotic consisting of high amounts
of six strains of lactic acid bacteria normally found in the human colon will favorably
support and maintain bowel function moderating or obviating IAD. |
| Criteria: |
|
Inclusion Criteria:
- all subjects aged >/= 18 years who qualify to receive a living (related or unrelated)
or cadaveric kidney allograft using steroid free induction immunosuppression.
- single organ recipient (kidney only)
- subjects receiving first or second renal transplant
- women of child-bearing potential should have a negative serum pregnancy test within 1
week prior to beginning study medications
- subjects with no known contraindications to treatment with any of the study drugs
- subjects providing written consent
- subjects who are compliant and able to complete all the necessary assessment
procedures
Exclusion Criteria:
- Subjects < 18 years of age
- Subjects who do not meet criteria for steroid free protocol
- subjects with known intolerance to lactobacillus
- subjects with history of chronic diarrhea
- subjects with history of gastrointestinal disorder that may interfere with their
ability to absorb oral medication: inflammatory bowel disease, irritable bowel
syndrome, short gut syndrome, or ileo jejunal surgery
- subjects with known laxative abuse
- subjects with pancreatic insufficiency
- subjects who are pregnant, lactating or nursing
- subjects with active peptic ulcer disease
- child bearing women not willing to use a reliable form of contraception
- subjects with prior history of C. difficile
- subjects receiving other medications considered to be experimental for control of
diarrhea |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 15, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|